Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091598 · ClinicalTrials.gov registry record · Phase 3
ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 372
- Enrollment target
NCT00091598 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 372 participants.
The verdict
NCT00091598, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 372 participants
- Enrollment target
Study Summary
The primary objective is to determine the effect of ambrisentan on exercise capacity in subjects with PAH.
Interventions
- DRUG Ambrisentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2004-01 |
| Est. Completion | 2006-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00091598
The ClinicalTrials.gov registry entry for NCT00091598 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 372 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ambrisentan is the first listed.
NCT00091598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00091598 about?
NCT00091598 is a clinical study titled "ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)". The primary objective is to determine the effect of ambrisentan on exercise capacity in subjects with PAH.
What is the current status of trial NCT00091598?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 372 participants. The study started on 2004-01. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00091598?
The interventions under investigation include: Ambrisentan (DRUG).
Who is sponsoring clinical trial NCT00091598?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.